Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Liposomal Bupivacaine Nerve Block for Knee Replacement Pain: Added Value and Optimization

Added Value and Optimization Strategies of Liposomal Bupivacaine Targeted Nerve Block in Multimodal Analgesia for Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Three-Arm Controlled Clinical Trial

Background Total knee arthroplasty (TKA) effectively relieves end-stage knee osteoarthritis, yet moderate-to-severe postoperative pain substantially compromises early functional exercise and rehabilitation. Liposomal bupivacaine, with a duration of action of up to 72 hours, offers a means of extending the postoperative pain-free window. However, previous studies have been limited by non-standardized background analgesia, absent head-to-head comparison of block targets, reliance on short-term resting pain scores, and inadequate blinding. Consequently, both the added value of liposomal bupivacaine nerve block on top of intravenous patient-controlled analgesia (IV-PCA) plus local infiltration analgesia (LIA), and the optimal block target, remain unresolved.

Objective To determine the analgesic added value of a single-shot liposomal bupivacaine targeted nerve block superimposed on standardized multimodal analgesia, and to compare the analgesic and functional recovery profiles of alternative block targets, thereby informing an optimized perioperative analgesic strategy.

Methods In this prospective, randomized, double-blind, three-arm controlled trial, 〔n〕 patients scheduled for unilateral TKA will be randomized to 〔arms to be confirmed: (1) background analgesia alone; (2) adductor canal block (ACB); (3) ACB combined with IPACK block〕. All patients receive standardized background analgesia comprising IV-PCA and intraoperative LIA. The primary endpoint is movement-evoked pain numeric rating scale (NRS) score at 〔24〕 h postoperatively. Secondary endpoints include resting pain scores, cumulative opioid consumption, time to first ambulation, knee range of motion, incidence of postoperative nausea and vomiting (PONV), and length of hospital stay.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

210

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år til 85 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:Age 65 to 85 years at the time of surgery. Scheduled for elective unilateral total knee arthroplasty for end-stage knee osteoarthritis.

Body mass index ≥18.5 and <25 kg/m². American Society of Anesthesiologists (ASA) physical status I to III. Written informed consent obtained from the patient before any study procedure. Able to understand and use the numeric rating scale (NRS) for pain and to complete the quality-of-recovery questionnaire.

Exclusion Criteria:Refusal to participate, or withdrawal of consent at any time.

Known allergy or hypersensitivity to bupivacaine, ropivacaine, oxycodone, or other study-related medications.

Infection at or near the planned puncture sites, or systemic infection. Coagulopathy, or current anticoagulant/antiplatelet therapy that precludes deep peripheral nerve block.

Pre-existing peripheral neuropathy, motor or sensory deficit in the operated limb, or other contraindication to neuraxial/peripheral block.

Chronic opioid use (≥3 months) or a history of opioid dependence. Severe hepatic or renal impairment (e.g. eGFR <30 mL/min/1.73 m², or Child-Pugh class B/C).

Severe cardiopulmonary disease (e.g. unstable angina, NYHA class III-IV heart failure, severe COPD), or ASA physical status IV or higher.

Preoperative knee flexion contracture >15° or varus deformity >15°, or previous surgery on the index knee (including prior arthroplasty).

Cognitive impairment, psychiatric disorder, illiteracy, or language barrier that would prevent valid pain and recovery assessment.

Participation in another interventional trial within 30 days. Vulnerable populations: minors, pregnant or lactating women, prisoners, and persons unable to give voluntary informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Adductor Canal Block (ACB)

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

Eksperimentel: ACB Plus IPACK Block

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

A single-shot IPACK (interspace between the popliteal artery and the capsule of the posterior knee) block is performed with the patient supine and the knee flexed approximately 30 degrees. A high-frequency linear transducer is positioned in the popliteal crease with the popliteal artery identified in short axis, and a 22-gauge needle is advanced in-plane from medial to lateral until the tip lies in the fascial plane between the popliteal artery and the posterior capsule of the knee. After negative aspiration, the study solution is injected with real-time visualization of spread along this plane, without puncturing the popliteal vessels.

Ingen indgriben: Background Analgesia Alone

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Patients Achieving Pain-Free Rehabilitation Within 72 Hours After Surgery (Composite)
Tidsramme: 72 hours after surgery

Composite primary endpoint, defined as the proportion of patients meeting all three of the following criteria within 72 hours after surgery: (1) adequate pain control-numeric rating scale (NRS) score ≤3 for movement-evoked pain during 45° knee flexion at 24, 48, and 72 hours postoperatively; (2) functional progress-ability to walk ≥20 m with assistance within 72 hours; and (3) opioid sparing-cumulative intravenous oxycodone consumption ≤40 mg (or morphine-equivalent dose) from 0 to 72 hours postoperatively.

72 hours after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • KY-2026-148

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .